10 Nov 1999 Becton, Dickinson and Company has received clearance by the FDA to market its BDProbeTec ET System for the direct qualitative detection of Chlamydia trachomatis and Neisseria gonorrhoeae, two of the most common causes of STDs. The test has been cleared for use with endocervical swabs, male urethral swabs, and with female and male urine.
Many clinicians recognize that chlamydia and gonorrhea are significant health issues.
We believe the BDProbeTec ET System will help improve screening for these diseases in the large number of men and women who are infected but who do not have clinical symptoms. The system is designed to enhance productivity through increased instrument throughput, optimal workflow, and decreased time to result, and to improve result integrity through SDA sensitivity, pre-dispensed dried reagents and incorporation of an amplification control to identify inhibitory specimens. No part of this publication may be redistributed in any form without prior permission. Terms and conditions for users . Privacy policy .